When bound by ligands like neuregulin, ERBB4 activates numerous downstream pathways, including Ras/MAPK/ERK and PI3K/AKT signaling (via mTOR), to regulate both normal cellular processes and cancer development and progression [23–25]. Here, MAPK1 is linked to cancer.